Galera Therapeutics Inc. (NASDAQ: GRTX) converted its remaining 42,839.11 shares of Series B Non-Voting Convertible Preferred Stock into 42,839,103 shares of common stock on May 15, 2026, according to a company statement.

The conversion was conducted under the Certificate of Designation of Preferences, Rights and Limitations of the Series B Non-Voting Convertible Preferred Stock. The company did not issue fractional shares in connection with the mandatory conversion, instead providing cash payments to holders equal to the trading value of fractional shares as of the close of business on the conversion date.

Following the conversion, no shares of Series B Preferred Stock remain outstanding. Both the preferred and common stock carry a par value of $0.001 per share.